DLO acquires Cleveland HeartLab for Oklahoma

Diagnostic Laboratory of Oklahoma (DLO) has announced that it has completed its acquisition of Cleveland HeartLab business in Oklahoma. As a joint venture of Quest Diagnostics and INTEGRIS Health, DLO will take part in Quest's first national center of excellence focused on heart disease diagnostics within Cleveland HeartLab's existing clinical laboratory facility in Cleveland.

The acquisition combines the expertise of Cleveland HeartLab's personalized evaluation of heart disease risk based on inflammation and other markers with Quest's Cardio IQ® lipid particle analysis and genetic and metabolic testing leadership. Heart disease is the number one cause of death in the United States. Conventional laboratory tests to assess cardiovascular disease, such as cholesterol panels, may not identify risk in all patients. New inflammation, genetic and other biomarkers may help physicians identify at-risk patients and guide treatment protocols to improve outcomes.

"Heart disease is the leading cause of death in Oklahoma," said DLO CEO Dennis Hogle. "By partnering with Cleveland HeartLab, DLO now offers innovative cardiometabolic diagnostic testing to the citizens of Oklahoma that can help identify potential risks, allowing for early intervention and treatment to achieve the best possible health outcomes."

In connection with the acquisition, Quest Diagnostics and Cleveland Clinic have also finalized a strategic collaboration intended to speed the commercialization of emerging innovations at Cleveland Clinic, including its Lerner Research Institute. The two entities also intend to collaborate on trials to demonstrate the clinical and economic value of these and other biomarkers. For 24 years in a row, the Cleveland Clinic has been ranked the best hospital in the country for cardiology and heart surgery by the U.S. News & World Report.